People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Hennepin Life Sciences, Llc | — | Biotechnology | Seed | $1.9M | $82.2M | 2016 |
| ImmuVen, Inc. | — | Biotechnology | Pre-Seed | $710K | $14.1M | 2009 |
| Niche Biopharmaceuticals LLC | — | Pharmaceuticals | Pre-Seed | $300K | $278K | 2023 |
Patrick M Schlievert at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Patrick M Schlievert on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Brennan | 1 | 3 |
| Daniel Saccani | 1 | 2 |
| Dayton Reardan | 1 | 1 |
| Patrick Schlievert | 1 | 1 |
| Robert M Klem | 1 | 1 |
| Douglas M. Wicks | 1 | 1 |
| Thomas Burke | 1 | 1 |
| John Bullion | 1 | 1 |
| Williamson Bradford | 1 | 1 |
| William Falkner | 1 | 1 |
| Shaun Andrikopoulos | 1 | 1 |
| Marnie Peterson | 1 | 1 |
| David M Kranz | 1 | 1 |
| Cheryl Lee Quinn | 1 | 1 |
| Timothy Charles Hoerr | 1 | 1 |
| Robert Klem | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.